Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agency Will Request More Voluntary Safety Data Disclosure By Sponsors

This article was originally published in The Pink Sheet Daily

Executive Summary

Controversy involving pediatric antidepressant use has encouraged FDA to accelerate public release of safety review data, Acting Deputy Commissioner for Policy Sachdev says. A planned partnership with CMS will also allow for better post-marketing safety surveillance.

You may also be interested in...



Pediatric Exclusivity Studies Will Be Included In Labeling, FDA Says

FDA is in the process of developing a policy for including results from studies conducted under the Best Pharmaceuticals for Children Act in labeling, Office of Medical Policy Director Temple says during House hearing on antidepressants.

FDA/CMS Formal Collaboration Will Include Data Sharing, Parallel Review

A draft memorandum of understanding is under review at both agencies, Centers for Medicare & Medicaid Services Chief Medical Officer Sean Tunis, MD, told the BIO annual meeting in San Francisco. The MOU will address parallel review for new technologies, and allow the agencies to share scientific expertise and data.

Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal

A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability

Topics

UsernamePublicRestriction

Register

PS058112

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel